Open AccessAnti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis
Author(s) -
Sara Sabbagh,
Iago PinalFernandez,
Takayuki Kishi,
Ira N. Targoff,
Frederick W. Miller,
Lisa G. Rider,
Andrew L. Mammen
Publication year - 2019
Publication title -
annals of the rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.333
H-Index - 240
eISSN - 1468-2060
pISSN - 0003-4967
DOI - 10.1136/annrheumdis-2018-215004
Subject(s) - autoantibody , juvenile dermatomyositis , medicine , myositis , dermatomyositis , interstitial lung disease , polymyositis , connective tissue disease , immunology , pathology , disease , autoimmune disease , antibody , lung
Anti-Ro52 autoantibodies are associated with more severe interstitial lung disease (ILD) in adult myositis patients with antiaminoacyl transfer (t)RNA synthetase autoantibodies. However, few studies have examined anti-Ro52 autoantibodies in juvenile myositis. The purpose of this study was to define the prevalence and clinical features associated with anti-Ro52 autoantibodies in a large cohort of patients with juvenile myositis.